List of Excipients in Branded Drug PROSCAR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	PROSCAR	finasteride	0006-0072	ALUMINUM OXIDE
Merck Sharp & Dohme Corp	PROSCAR	finasteride	0006-0072	CELLULOSE, MICROCRYSTALLINE
Merck Sharp & Dohme Corp	PROSCAR	finasteride	0006-0072	DOCUSATE SODIUM
Merck Sharp & Dohme Corp	PROSCAR	finasteride	0006-0072	FD&C BLUE NO. 2

Proscar Excipient Strategy and Commercial Opportunities for Finasteride 5 mg

Last updated: October 16, 2026

Proscar is the branded 5 mg finasteride tablet for benign prostatic hyperplasia, or BPH. Its core formulation is mature, low-cost and widely replicated by generic manufacturers. The commercial opportunity is therefore concentrated in excipient optimization, patient-use differentiation, manufacturing efficiency, supply reliability and targeted delivery formats rather than in exclusivity around the active ingredient.

What is Proscar and how is it regulated?

Proscar contains finasteride, a type II 5-alpha-reductase inhibitor. The FDA approved Proscar 5 mg tablets for the treatment of symptomatic BPH in 1992. Finasteride reduces conversion of testosterone to dihydrotestosterone and can reduce prostate volume, improve urinary symptoms and lower the risk of acute urinary retention and BPH-related surgery.[1]

Product attribute	Proscar profile
Brand	Proscar
Active ingredient	Finasteride
Strength	5 mg
Dosage form	Film-coated oral tablet
Primary indication	BPH
Original sponsor	Merck
U.S. NDA	019897
FDA approval	1992
Reference product status	Mature, off-patent product
Generic availability	Yes
Primary commercial market	Low-cost generic finasteride 5 mg

Proscar is also distinct from Propecia, which contains finasteride 1 mg for male-pattern hair loss. The two products share the active ingredient but have different strengths, labeling, commercial positioning and product-use risks.

What excipients are used in Proscar tablets?

The Proscar formulation uses conventional direct-compression or granulation-compatible tablet excipients. FDA labeling identifies lactose monohydrate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate, docusate sodium, magnesium stearate and film-coating components.[1,2]

Proscar excipient functions

Excipient or excipient class	Likely formulation role
Lactose monohydrate	Diluent and tablet mass builder
Microcrystalline cellulose	Diluent, binder and compactability enhancer
Pregelatinized starch	Binder and disintegration support
Sodium starch glycolate	Superdisintegrant
Docusate sodium	Wetting aid and dissolution-support excipient
Magnesium stearate	Lubricant
Hypromellose or related coating polymers	Film coating
Titanium dioxide and colorants	Opacity and product identification
Talc	Coating process aid

The formulation is commercially conservative. It relies on widely available, compendial excipients with established use in immediate-release tablets. That reduces regulatory complexity and supports multiple contract manufacturing sources.

The formulation also reflects a practical balance among tablet hardness, disintegration, dissolution, coating performance and manufacturing cost. Because finasteride is administered at only 5 mg, most of the tablet mass is excipient rather than active pharmaceutical ingredient.

What excipient strategy is appropriate for generic finasteride 5 mg?

A generic Proscar strategy should prioritize bioequivalence, content uniformity, low defect rates and stable dissolution rather than novelty. The strongest formulation position is likely to come from process robustness and supply-chain control.

1. Preserve immediate-release performance

A conventional immediate-release tablet is the lowest-risk platform for an abbreviated new drug application. The target profile should include:

• Rapid and consistent disintegration
• Reliable dissolution across pH conditions
• Low friability
• Adequate hardness for packaging and distribution
• Uniform low-dose finasteride distribution
• Stable film coating
• Minimal sensitivity to lubricant overmixing

Because finasteride represents a small percentage of tablet weight, content uniformity is a central manufacturing issue. Segregation, poor blending and nonuniform distribution can create more regulatory risk than the choice of an innovative excipient.

2. Manage lactose and patient-specific tolerability

Lactose is a cost-effective filler, but lactose-free formulations can target patients with lactose intolerance, excipient sensitivity or preference for simplified formulations. A lactose-free version could replace lactose with one or more of the following:

• Mannitol
• Dibasic calcium phosphate
• Additional microcrystalline cellulose
• Coprocessed cellulose-based excipients
• Spray-dried mannitol or other directly compressible polyols

A lactose-free product would not automatically create meaningful clinical differentiation. Its value would depend on demonstrated manufacturing performance, clear labeling and distribution through pharmacies or health systems that actively manage excipient preferences.

3. Evaluate low-force and high-speed tableting

Coprocessed excipients may allow manufacturers to reduce granulation steps and improve tableting speed. Potential targets include:

• Lower compression-force requirements
• Reduced sticking and picking
• Better flow into the tablet press
• Narrower tablet-weight variation
• Lower lubricant sensitivity
• Reduced granulation energy and water use

The commercial benefit is primarily manufacturing margin. It is less likely to support strong product exclusivity unless the formulation or process is protected by a defensible patent and produces measurable performance advantages.

4. Control coating and visual identification

Proscar tablets use film coating for appearance, swallowability, protection and product identification. Generic manufacturers can improve the coating system through:

• Lower coating weight
• Faster drying
• Reduced solvent or water use
• Improved color reproducibility
• Better resistance to abrasion
• Distinctive but compliant tablet markings

A distinctive appearance can reduce dispensing errors, but tablet color alone is generally weak intellectual property. The commercial protection comes from trademark, packaging and pharmacy recognition rather than from the excipient composition.

What safety issue affects Proscar excipient and dosage-form design?

Finasteride tablets should not be handled by women who are or may become pregnant when the tablets are crushed or broken. The active ingredient can be absorbed through the skin and may cause abnormalities in the external genitalia of a male fetus.[1]

This warning has direct implications for formulation design and packaging. A product that minimizes tablet breakage, powder generation and coating damage has a practical safety advantage.

Relevant design measures

• Maintain a robust film coat.
• Avoid unnecessary tablet splitting.
• Use high-integrity blister packaging where appropriate.
• Include handling instructions on the label and carton.
• Evaluate friability after shipping and thermal cycling.
• Avoid dosage forms that create loose finasteride powder during normal use.
• Consider unit-dose packaging for institutional or assisted-care settings.

An orally disintegrating tablet, chewable tablet or powder sachet could increase handling exposure unless the formulation is engineered to prevent residue and the labeling addresses occupational and household handling. Convenience alone does not justify a more dispersible dosage form.

What formulation patents protect Proscar and generic finasteride?

The principal commercial patent opportunity around Proscar has expired. Finasteride has been available from multiple generic manufacturers for many years, and the original brand has no practical composition-of-matter exclusivity remaining in the United States.

Exclusivity category	Current commercial position
Finasteride active-ingredient patent	Expired
Original Proscar product protection	Expired
FDA new-drug exclusivity	Expired
Generic 5 mg tablets	Commercially established
Formulation improvement opportunity	Available only through new product development
Current Paragraph IV threat to Proscar	Not commercially central because generic entry has already occurred

The key distinction is between expired protection for the original product and possible new protection for a later formulation. A new excipient system may support a patent only if it produces a non-obvious technical result, such as improved stability, dissolution, manufacturability or abuse-resistant handling. A simple substitution of lactose for mannitol or one binder for another would generally face obviousness risk.

Potentially protectable subject matter could include:

• A specific excipient ratio linked to a defined dissolution profile
• A low-segregation manufacturing process for low-dose finasteride tablets
• A coating system that reduces powder shedding
• A stable formulation with improved resistance to humidity
• A modified-release product with a clinically relevant dosing advantage
• A combination product with another BPH therapy
• A unit-dose packaging system that reduces occupational exposure

Patent value would depend on claim scope, prosecution history, freedom to operate and the ability to demonstrate a meaningful technical effect.

What is the Orange Book status of Proscar?

Proscar is an older FDA-approved reference product with generic competition. The FDA Orange Book remains the principal source for current listed patents, therapeutic-equivalence codes and approved product information.[3]

For a new finasteride 5 mg generic, the likely regulatory path is an ANDA referencing the listed drug. The applicant would normally demonstrate pharmaceutical equivalence and bioequivalence rather than repeat the full clinical development program required for an NDA.

Because the original product is already subject to generic competition, a new applicant is more likely to pursue:

• ANDA approval for standard finasteride 5 mg tablets
• A 505(b)(2) application for a materially different dosage form
• A combination-product strategy
• A branded-generic strategy with differentiated packaging or supply guarantees

A formulation that changes release characteristics, route of administration or clinical use may fall outside the conventional ANDA pathway.

When does Proscar lose exclusivity and what does that mean commercially?

Proscar lost meaningful U.S. exclusivity years ago. The commercial consequences are clear:

1. Price competition is intense.
2. Pharmacy substitution favors approved generics.
3. Active-ingredient differentiation is unavailable.
4. Manufacturing cost and supply reliability determine margin.
5. Branding has value mainly in adherence, channel access and physician recognition.
6. Reformulation must create a practical benefit to justify development costs.

Revenue exposure for the original brand is difficult to isolate because finasteride 5 mg is sold through multiple generic labels, wholesalers and pharmacy channels. The relevant market is the aggregate U.S. and international finasteride 5 mg market, not only sales under the Proscar name.

What commercial opportunities exist in Proscar excipients?

Opportunity 1: Lactose-free generic finasteride

A lactose-free tablet is the most straightforward excipient-led concept. It could be positioned for patients with lactose intolerance or for formularies seeking simplified excipient profiles.

Commercial limitations include:

• Limited clinical differentiation
• Low switching friction between generic products
• Potentially higher excipient cost
• Need to validate compression and dissolution
• Weak protection against competing lactose-free products

Opportunity 2: Low-shed film-coated tablet

A robust film coat could address the pregnancy-related handling warning. The product could target household use, long-term-care facilities and pharmacies seeking reduced tablet breakage.

The opportunity is strongest if supported by comparative powder-shedding data, packaging studies and a validated manufacturing process. Marketing claims would need to remain consistent with FDA labeling and applicable promotional rules.

Opportunity 3: Unit-dose packaging

Blister packaging or calendarized unit-dose formats could improve adherence and reduce handling of loose tablets. This is more likely to create commercial differentiation than a minor binder change.

Potential customers include:

• Mail-order pharmacies
• Medicare and managed-care channels
• Long-term-care facilities
• Hospital discharge programs
• Patients using multiple chronic medicines

Packaging patents, trade dress and channel agreements may provide more practical protection than an excipient patent.

Opportunity 4: Orally disintegrating or mini-tablet formats

An orally disintegrating finasteride product could target patients with dysphagia or difficulty swallowing conventional tablets. Mini-tablets may support flexible administration, but both formats create added development and handling considerations.

The main risks are:

• Increased exposure to dispersed finasteride
• Taste masking requirements
• Greater manufacturing complexity
• Need to establish acceptable dissolution and stability
• Possible need for an NDA or 505(b)(2) pathway rather than a simple ANDA

Opportunity 5: Combination therapy

Finasteride is often used in BPH treatment alongside an alpha blocker such as tamsulosin. A fixed-dose combination could improve adherence and reduce pill burden.

This strategy would face:

• Combination-product development requirements
• Dose-ratio selection
• Drug-drug interaction assessment
• Stability testing for both actives
• Potential patent and regulatory issues around the partner drug
• Reimbursement and formulary competition

Combination products are more commercially defensible than routine excipient substitutions, but they require materially higher development investment.

How does Proscar compare with competing BPH drugs?

Product or class	Main active ingredient	Formulation opportunity	Commercial position
Proscar/generic finasteride	Finasteride 5 mg	Lactose-free, low-shed, ODT, combination	Mature generic market
Avodart/generic dutasteride	Dutasteride	Softgel optimization, combination products	Mature 5-alpha-reductase inhibitor market
Flomax/generic tamsulosin	Tamsulosin	Modified-release capsule or tablet	High-volume alpha-blocker market
Jalyn/generic combination	Dutasteride/tamsulosin	Fixed-dose combination	Adherence-driven opportunity
Silodosin	Silodosin	Modified-release oral products	Competes for symptom-focused treatment

Finasteride has a slower onset than alpha blockers and is most commercially relevant for patients with enlarged prostate risk and longer-term disease modification. A formulation strategy should therefore focus on persistence, refill convenience and safe household handling rather than rapid symptom relief.

Which companies are challenging the Proscar market?

The market is challenged primarily by generic manufacturers rather than by Paragraph IV litigants. Multiple manufacturers have marketed finasteride 5 mg tablets under ANDAs, including large generic companies and authorized or regional suppliers. Competition typically centers on:

• Wholesale acquisition cost
• Medicaid and managed-care contracts
• Supply continuity
• DEA and controlled-substance logistics are not central because finasteride is not a controlled substance
• Tablet availability and packaging
• Manufacturing location
• Product recalls and shortage exposure
• Pharmacy benefit manager placement

No biosimilar risk applies. Finasteride is a small-molecule drug, not a biologic, so competition proceeds through generic-drug pathways rather than biosimilar applications.

What manufacturing and intellectual-property barriers remain?

The active ingredient is not the main barrier. The remaining barriers are operational and regulatory.

Manufacturing barriers

• Low-dose content uniformity
• Powder segregation
• Tablet sticking and picking
• Coating uniformity
• Stability under humidity
• Sourcing of consistent-grade excipients
• Process validation at commercial scale
• Packaging integrity
• Control of tablet breakage and powder shedding

Intellectual-property barriers

• Existing formulation patents for redesigned dosage forms
• Process patents covering granulation or coating
• Combination-product patents
• Packaging or handling patents
• Trade dress and trademarks
• Third-party patents covering excipient combinations or release systems

A freedom-to-operate review should cover the active ingredient, formulation claims, manufacturing process, packaging configuration and any proposed indication or combination.

What is the strongest commercial strategy for Proscar reformulation?

The highest-probability strategy is a standard immediate-release, film-coated 5 mg tablet with one or more practical improvements:

1. Lactose-free composition.
2. High tablet strength with low friability.
3. Low powder shedding.
4. Stable dissolution after humidity exposure.
5. Unit-dose or calendarized packaging.
6. Reliable multi-source excipient supply.
7. Competitive cost of goods.
8. Regulatory pathway aligned with the degree of formulation change.

A novel dosage form can create greater differentiation, but it also increases regulatory, safety and commercial risk. For a mature generic market, manufacturing economics and channel execution are likely to produce better returns than a highly engineered formulation without a clear reimbursement or adherence advantage.

Key Takeaways

• Proscar is a mature finasteride 5 mg BPH product with expired original exclusivity and extensive generic competition.
• Its conventional excipient system uses lactose, microcrystalline cellulose, starch-based disintegrants, lubricant and film-coating materials.
• The strongest near-term opportunity is a robust, low-cost, possibly lactose-free immediate-release tablet.
• Low-shed coating and unit-dose packaging address the practical handling warning for pregnant women.
• Orally disintegrating and combination products offer greater differentiation but create higher regulatory and development burdens.
• No biosimilar pathway applies because finasteride is a small-molecule drug.
• Paragraph IV litigation is no longer the central market issue; manufacturing cost, supply reliability and channel access are more important.
• New patent value would need to come from a technically defensible formulation, process, packaging or combination claim.

FAQs

Can finasteride 5 mg tablets be made without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate or another suitable diluent. The replacement requires validation of content uniformity, hardness, disintegration, dissolution and stability.

Is an orally disintegrating Proscar tablet commercially attractive?

It could address dysphagia and adherence, but it would increase taste-masking, handling and regulatory complexity. The product would need a clear patient benefit to justify development costs.

Can an excipient change create new patent protection for finasteride?

Yes, but only where the claimed composition or process is novel and non-obvious and produces a defensible technical effect. Routine substitution of one common filler or binder is unlikely to provide strong protection.

Does finasteride require a biosimilar application?

No. Finasteride is a small-molecule drug. A conventional generic product generally uses the ANDA pathway, while materially different dosage forms may require an NDA or 505(b)(2) application.

What is the best packaging format for finasteride 5 mg?

A high-integrity blister or unit-dose package can reduce tablet breakage, improve adherence and limit handling of loose tablets. The optimal format depends on manufacturing cost, pharmacy distribution and target patient population.

References

1. U.S. Food and Drug Administration. (2023). Proscar (finasteride) tablets, 5 mg: Prescribing information. FDA.

2. National Library of Medicine. (2024). DailyMed: Proscar- finasteride tablet, film coated. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, 44th edition. FDA.